Medical Reproduction Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Department of Sports Medicine, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Biomed Res Int. 2021 Nov 23;2021:9485273. doi: 10.1155/2021/9485273. eCollection 2021.
MutS homolog 2 (MSH2), with the function of identifying mismatches and participating in DNA repair, is the "housekeeping gene" in the mismatch repair (MMR) system. MSH2 deficiency has been reported to enhance cancer susceptibility for the association of hereditary nonpolyposis colorectal cancer. However, the expression and prognostic significance of MSH2 have not been studied from the perspective of pan-cancer.
The GTEx database was used to analyze the expression of MSH2 in normal tissues. The TCGA database was used to analyze the differential expression of MSH2 in pan-cancers. The prognostic value of MSH2 in pan-cancer was assessed using Cox regression and Kaplan-Meier analysis. Spearman correlations were used to measure the relationship between the expression level of MSH2 in pan-cancer and the level of immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI).
MSH2 is highly expressed in most type of cancers and significantly correlated with prognosis. In COAD, KIRC, LIHC, and SKCM, the expression of MSH2 was significantly positively correlated with the abundance of B cells, CD4+ T cells, CD8+ T cells, dendritic cells, macrophages, and neutrophils. In THCA, MSH2 expression correlated with CD8+T Cell showed a significant negative correlation. MSH2 had significantly negative correlations with stromal score and immune score in a variety of cancers and significantly correlated with TMB and MSI of a variety of tumors.
MSH2 may play an important role in the occurrence, development, and immune infiltration of cancer. MSH2 can emerge as a potential biomarker for cancer diagnosis and prognosis.
MutS 同源物 2(MSH2)具有识别错配和参与 DNA 修复的功能,是错配修复(MMR)系统中的“管家基因”。MSH2 缺陷已被报道增强了遗传性非息肉病性结直肠癌的癌症易感性。然而,从泛癌的角度来看,MSH2 的表达和预后意义尚未得到研究。
使用 GTEx 数据库分析 MSH2 在正常组织中的表达。使用 TCGA 数据库分析 MSH2 在泛癌中的差异表达。使用 Cox 回归和 Kaplan-Meier 分析评估 MSH2 在泛癌中的预后价值。Spearman 相关性用于测量 MSH2 在泛癌中的表达水平与免疫浸润、肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)水平之间的关系。
MSH2 在大多数类型的癌症中高表达,与预后显著相关。在 COAD、KIRC、LIHC 和 SKCM 中,MSH2 的表达与 B 细胞、CD4+T 细胞、CD8+T 细胞、树突状细胞、巨噬细胞和中性粒细胞的丰度呈显著正相关。在 THCA 中,MSH2 表达与 CD8+T 细胞呈显著负相关。MSH2 与多种癌症的基质评分和免疫评分呈显著负相关,与多种肿瘤的 TMB 和 MSI 呈显著正相关。
MSH2 可能在癌症的发生、发展和免疫浸润中发挥重要作用。MSH2 可以成为癌症诊断和预后的潜在生物标志物。